Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predictive model for prognosis in advanced diffuse histiocytic lymphoma.

L Danieu, G Wong, B Koziner

    Cancer Research
    |October 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Recombinant Interferon Alpha-2b in Patients with Progressive and/or Recurrent Hodgkin's Disease.

    Leukemia & lymphoma·2016
    Same author

    Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC).

    Leukemia & lymphoma·2016
    Same author

    Safety trial of Floseal(®) haemostatic agent in head and neck surgery.

    Annals of the Royal College of Surgeons of England·2012
    Same author

    Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.

    Blood cancer journal·2012
    Same author

    International consensus on (ICON) pediatric asthma.

    Allergy·2012
    Same author

    mTOR inhibitors: a myth, a cure for cancer or something in between?

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2012

    A new predictive model using serum lactic dehydrogenase (LDH) and level of site involvement (LSI) accurately predicts survival in advanced diffuse histiocytic lymphoma patients. This model offers improved prognostic staging over the Ann Arbor system.

    Area of Science:

    • Oncology
    • Hematology
    • Biostatistics

    Background:

    • Advanced diffuse histiocytic lymphoma (DHL) presents a significant challenge in predicting patient outcomes.
    • Current staging systems, such as the Ann Arbor system, may not adequately differentiate prognostic groups for DHL.

    Purpose of the Study:

    • To validate a predictive model for treatment response and survival in advanced diffuse histiocytic lymphoma.
    • To identify key prognostic factors beyond traditional staging.

    Main Methods:

    • Retrospective review of 127 advanced DHL patients treated between 1974-1984.
    • Analysis of factors including age, sex, Ann Arbor stage, prior therapy, B symptoms, serum lactic dehydrogenase (LDH), and sites of initial disease (LSI).
    • Multivariate logistic regression and parametric Weibull survival analysis were employed.

    Related Experiment Videos

    Main Results:

    • Serum LDH, LSI, and age were identified as significant predictors of response and survival.
    • The Ann Arbor staging system did not effectively stratify patients by prognosis.
    • A novel four-stage prognostic model based on LDH levels and LSI demonstrated significant differences in 48-month survival rates (ranging from 80% to 15%).

    Conclusions:

    • Serum LDH and LSI provide a more accurate prognostic stratification for advanced DHL than the Ann Arbor stage.
    • This LDH and LSI-based model can facilitate more precise comparisons across clinical trials for advanced DHL patients.